| Age | Median | 57.5 years old | (range: 33 - 79 years) |
|
| ≥50 years |
| 121 |
|
| <50 years |
| 43 |
| Follow-up period | 3 - 5 years |
|
|
|
| −3 years |
| 57 |
|
| −4 years |
| 37 |
|
| −5 years |
| 70 |
| Boost irradiation |
|
|
|
|
| No |
| 133 |
|
| Yes | 10 MeV electron | 26 |
|
|
| 7 MeV electron | 5 |
| Endocrine therapy |
|
|
|
|
| No 33 |
|
|
|
| Yes 131 | Aromatase inhibitor | 84 |
|
|
| Anti-estrogen | 47 |
| Chemotherapy |
|
|
|
|
| No 141 |
|
|
|
| Yes 24 | Post surgery before radiotherapy (EC 13, EC + D 4, ET 1, CEF 1) | 19 |
|
|
| Adjuvant (CMF 5) | 5 |
|
|
|
|
|